ClinicalTrials.gg
RecruitingNCT05406193Updated May 30, 2023

A New Care Model for Patients With Complicated Multimorbidity

An interventional study of Patient-centred complex intervention in complicated multimorbidity (CIM2) in Multimorbidity, sponsored by Slagelse Hospital. Recruiting at 11 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by Slagelse Hospital · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients with complex multimorbidity experience a high treatment burden, fragmentation of care and poor clinical outcomes. General practice is the key organizational setting in terms of offering these patients integrated, longitudinal, and patient-centered care. Therefore, we propose a new general practice based model to improve overview, patient involvement and integration of care. The new care model consist of a teaching session on multimorbidity for the health care professionals, a prolonged overview consultation for patients with complex multimorbidity with the general practitioner, resulting in an individual care plan shared with the municipalities and secondary care, access to cross-sectoral video conferences with secondary care specialists and. Control practices provide health care as usual. We evaluate the care model in a cluster-randomized non-blinded, parallel-group trial in general practice. Fourteen general practices are allocated 1:1 to either intervention or control. We evaluate the effectiveness of the intervention with patient-reported questionnaire at baseline, 6-month follow-up, and 12-month follow-up. Primary outcome measure is the Patient Assessment of Chronic Illness Care (PACIC). Secondary outcome measure includes patient-reported quality of life and the treatment burden for the patients with multimorbidity. Furthermore, the project include a process evaluation of the complex intervention with the objective to assess how the intervention is delivered and to identify important facilitators and barriers for implementing the intervention. The new model is integrated into the existing health care system structures and has the potential for a sustainable improvement in care for patients with complex multimorbidity.

02

Conditions studied

  • Multimorbidity

Keywords

  • General practice
  • Integrated care
  • Multimorbidity
03

In context

Lead sponsor

Slagelse Hospital is the lead sponsor of 21 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has more than one of the 3 common chronic diseases (diabetes, chronic obstructive pulmonary, chronic heart conditions)
  2. Has been hospitalised, or visited an outpatient clinic due to their chronic diseases during the previous year
  3. Take at least five different prescription drugs assessed from the Shared Medicine Card recording in the general practice
  4. The general practitioner or the nurse in the practice recognise the patient as a "demanding" patient with complicated multimorbidity that will benefit from an overview consultation.

Exclusion criteria

Exclusion Criteria:

  • Patients who cannot speak Danish,
  • Patients who cannot give ,
  • Patients who have a of less than 12 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Intervention (CIM2)

    An extended overview consultation, lasting 45 minutes, with the general practitioner, the patient (and maybe a relative), and the care coordinator. An individual care plan is developed, covering planned activities in the three sectors (general practice, municipality, and hospital) that will take place within the 12-month intervention period. General practice coordinates the planned patient care between general practice, the municipality, and the hospital, and follow-up on the execution of planned healthcare activities. The individual care plan is shared electronically with the healthcare center in the municipality and with the outpatient clinics using the standard IT-communication tool provided by MedCom and a routinely used national standard in general practice, hospitals, and municipalities.

    Other: Patient-centred complex intervention in complicated multimorbidity (CIM2)

  • No intervention
    Usual care

    Patients with a general practitioner allocated to the control group will receive usual care.

Interventions

  • OtherPatient-centred complex intervention in complicated multimorbidity (CIM2)

    CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity

06

What researchers measure

Primary outcomes

  1. Change from baseline Patient Assessment of Chronic Illness Care (PACIC) at 12 months

    PACIC is a 20-item patient report instrument that assesses patient's receipt of clinical services and actions. Each item was scored on a 5-point scale ranging from 1 (no or never) to 5 (yes or always). Respondents rate how often they experienced the content described in each item. The scale range from 1-5 and is scored by averaging of items completed within that scale, and the overall PACIC is scored by averaging scores across all 20 items. Higher scores indicate higher patient assessment delivery of high-quality care for patients with chronic diseases.

    Time frame: From baseline to 12-month follow-up

Secondary outcomes

  1. Change from baseline Patient Assessment of Chronic Illness Care (PACIC) at 6 months

    PACIC is a 20-item patient report instrument that assesses patient's receipt of clinical services and actions. Each item was scored on a 5-point scale ranging from 1 (no or never) to 5 (yes or always). Respondents rate how often they experienced the content described in each item. The scale range from 1-5 and is scored by averaging of items completed within that scale, and the overall PACIC is scored by averaging scores across all 20 items. Higher scores indicate higher patient assessment delivery of high-quality care for patients with chronic diseases.

    Time frame: From baseline to 6-month follow-up

  2. Change from baseline EuroQol-5 Domain (EQ-5D-5L) at 6 months

    The EQ-5D-5L assess the patients' health-related quality of life. It contains two main elements: a descriptive profile comprising five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and the EQ-5D visual analogue scale (EQ VAS). Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). The EQ-VAS range from 0 (the worst imaginable health state) at the bottom to 100 (the best imaginable health state) on the top for respondents to rate their overall health.

    Time frame: From baseline to 6-month follow-up

  3. Change from baseline EuroQol-5 Domain (EQ-5D-5L) at 12 months

    The EQ-5D-5L assess the patients' health-related quality of life. It contains two main elements: a descriptive profile comprising five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and the EQ-5D visual analogue scale (EQ VAS). Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). The EQ-VAS range from 0 (the worst imaginable health state) at the bottom to 100 (the best imaginable health state) on the top for respondents to rate their overall health.

    Time frame: From baseline to 12-month follow-up

  4. Change from baseline Multimorbidity Treatment Burden Questionnaire (MTBQ) at 6 months

    The Multimorbidity Treatment Burden Questionnaire (MTBQ) is a 10-item questionnaire designed to measure treatment burden (the effort of looking after one's health) in patients with multimorbidity in primary care. Each question is scored as follows: zero (not difficult/ does not apply), one (a little difficult), two (quite difficult), three (very difficult), four (extremely difficult). To calculate a global score, each participant's average score is calculated from the questions answered and multiplied by 25 to give a score from 0-100. Higher MTBQ score indicate higher treatment burden.

    Time frame: From baseline to 6-month follow-up

  5. Change from baseline Multimorbidity Treatment Burden Questionnaire (MTBQ) at 12 months

    The Multimorbidity Treatment Burden Questionnaire (MTBQ) is a 10-item questionnaire designed to measure treatment burden (the effort of looking after one's health) in patients with multimorbidity in primary care. Each question is scored as follows: zero (not difficult/ does not apply), one (a little difficult), two (quite difficult), three (very difficult), four (extremely difficult). To calculate a global score, each participant's average score is calculated from the questions answered and multiplied by 25 to give a score from 0-100. Higher MTBQ score indicate higher treatment burden.

    Time frame: From baseline to 12-month follow-up

07

Study locations

2 of 11 sites recruiting
  • Lægerne Kanaltorvet
    Albertslund, 2620, Denmark
    Active, not recruiting

    Not enrolling at this site.

  • Thorkil Christensen
    Albertslund, 2620, Denmark
    Active, not recruiting

    Not enrolling at this site.

  • Brøndbyøster Torv
    Brøndby, 2605, Denmark
    Active, not recruiting

    Not enrolling at this site.

  • Lægerne i Brohuset
    Ishøj, 2635, Denmark
    Active, not recruiting

    Not enrolling at this site.

  • Lægecenter Korsør
    Korsør, 4220, Denmark
    Active, not recruiting

    Not enrolling at this site.

  • Læge Depenau vej-Hansen
    Slagelse, 4200, Denmark
    Active, not recruiting

    Not enrolling at this site.

  • Læge Jørgen Larsen
    Slagelse, 4200, Denmark
    Withdrawn

    Not enrolling at this site.

  • Læge Lene Stiggaard
    Slagelse, 4200, Denmark
    Recruiting
    • Lene Stiggaard, GP · Contact
  • Lægerne Reventlow, Wolfhagen og Bendtsen
    Slagelse, 4200, Denmark
    Recruiting
    • Johan Reventlow, GP · Contact
  • Lægerne ved Lystskoven
    Slagelse, 4200, Denmark
    Active, not recruiting

    Not enrolling at this site.

  • Lægerne Vallensbæk Nord
    Vallensbæk, 2625, Denmark
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Apr 2024, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2022
First posted
Jun 6, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Apr 2024
CompletionEst.
May 2024
Last update
May 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05406193
Lead sponsor
Slagelse Hospital
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Nov 1, 2022
Primary completion
Apr 2024 (estimated)
Completion
May 2024 (estimated)
Last update
May 30, 2023

Study contacts

Anne Frølich, Professor
Contact
anfro@sund.ku.dk
+45 27121622
Sanne L Lundstrøm, Senior Researcher
Contact
sanlu@regionsjaelland.dk
51171721
Anne Frølich, Professor
study chair · Innovation and Research Centre for Multimorbidity, Slagelse hospital, Region Zealand

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion